GUJARAT THEMIS BIOSYN
|
|
BOM : 506879     NSE : GUJTHEMIS     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Nov 26,2024 |
Price(EOD): ₹ 325.95
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 3,552.86 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
GUJARAT THEMIS BIOSYN | -0.6% | 9% | 156.8% |
SUN PHARMACEUTICAL INDUSTRIES | -0.9% | -4.8% | 50.2% |
CIPLA | 1.5% | 0.1% | 19.9% |
DR REDDYS LABORATORIES | -0.4% | -8.2% | 7.1% |
ZYDUS LIFESCIENCES | 0.6% | -5.3% | 51% |
DIVIS LABORATORIES | 3% | 5.9% | 65% |
MANKIND PHARMA | 0.6% | 3.1% | 34.4% |
TORRENT PHARMACEUTICALS | 4.3% | -2.7% | 54.2% |
LUPIN | -0.1% | -4.4% | 72.4% |
FUNDAMENTAL ANALYSIS OF GUJARAT THEMIS BIOSYN
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF GUJARAT THEMIS BIOSYN
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
67.39
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 52.70 Cr
[Latest Qtr - Sep2024 - Standalone Results ] 17.64
P/B Calculated based on Book Value of Rs 201.38 Cr
[Latest Year - Mar2024 - Standalone Results ] 23
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Sep2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
387% 810% 876% |
SHARE PRICE MOMENTUM OF GUJARAT THEMIS BIOSYN
GUJARAT THEMIS BIOSYN vs SENSEX
DEBT OF GUJARAT THEMIS BIOSYN
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0 0 0 - |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF GUJARAT THEMIS BIOSYN
Pledged Promoter Shares |
3.3 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF GUJARAT THEMIS BIOSYN
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-10.59% -17.03% -20.54% -20.17% |
-12.21% -7.97% -15.95% -15.75% |
QtrlyTrend |
-8 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
GUJARAT THEMIS BIOSYN related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE SMALL CAP | 3.7% | -0.2% | 35.7% |
S&P BSE MIDSMALLCAP | 3.6% | -0.5% | 36.5% |
S&P BSE HEALTHCARE | 2.4% | 1% | 45.8% |
S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
You may also like the below Video Courses
FAQ about GUJARAT THEMIS BIOSYN
Is GUJARAT THEMIS BIOSYN good for long term investment?
As on Nov 26,2024, the Fundamentals of GUJARAT THEMIS BIOSYN look Strong and hence it may be good for long term investment! See Financial Performance of GUJARAT THEMIS BIOSYN . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is GUJARAT THEMIS BIOSYN UnderValued or OverValued?
As on Nov 26,2024, GUJARAT THEMIS BIOSYN is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of GUJARAT THEMIS BIOSYN ?
As on Nov 26,2024, the Intrinsic Value of GUJARAT THEMIS BIOSYN is Rs. 35.83 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 66.88
Fair Value [Median EV / Sales Model] : Rs. 35.83
Fair Value [Median Price / Sales Model] : Rs. 33.39
Estimated Median Fair Value of GUJARAT THEMIS BIOSYN : Rs. 35.83
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.